Publications by authors named "G S Palapattu"
Background And Objective: Prostate cancer (PC) in the transition zone (TZ) has better prognosis than peripheral-zone (PZ) PC despite higher prostate-specific antigen (PSA) in patients with TZ tumors. Our aim was to characterize molecular differences between TZ and PZ tumors and their clinical implications.
Methods: We performed spatial whole-transcriptome analyses of 50 regions of interest (ROIs) from three patients with PZ and/or TZ PC.
Article Synopsis
- * Experts in the field gathered to discuss and improve the language surrounding this disease to make it less intimidating.
- * The goal is to establish a clearer and more accurate way to define the nomenclature related to advanced prostate cancer for better patient understanding.
Article Synopsis
- There is growing recognition that prostate cancer patients often have germline variants that can have significant implications for their health and that of their families, necessitating a deeper understanding of which individuals may carry these variants.
- A study involving 505 prostate cancer patients was conducted, tracking various factors and evaluating the presence of pathogenic or likely pathogenic (P/LP) germline variants through genetic testing aligned with NCCN guidelines.
- The study found that the occurrence of P/LP variants was similar across different age groups and clinical characteristics, with only the age at testing in metastatic patients showing a predictive association for these variants, indicating challenges in refining existing clinical guidelines.
Objective: To assess the distribution of key mutations across tumour sizes in clear-cell renal cell carcinoma (ccRCC), and secondarily to examine the prognostic impact of aggressive mutations in smaller ccRCCs.
Patient And Methods: The distribution of mutations (VHL, PBRM1, SETD2, BAP1 and CDKN2A loss) across tumour sizes was assessed in 1039 ccRCCs treated with nephrectomy in cohorts obtained from the Tracking Cancer Evolution (TRACERx), The Cancer Genome Atlas (TCGA) and the Cancer Genomics of the Kidney (CAGEKID) projects. Logistic regression was used to model the presence of each mutation against size.
Introduction: The purpose of this study was to investigate the association between baseline androgen concentrations and outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line enzalutamide or abiraterone acetate plus prednisone (AAP).
Materials And Methods: We previously randomized men with mCRPC to enzalutamide or AAP to compare side-effects and measured androgen concentrations. In this post-hoc analysis, patients were grouped in quartiles (Q) based on their serum androgen values.